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ABSTRACT
In this issue of Clinical Kidney Journal, Plasse et al. report on the use of high-dose aliskiren as an adjunct therapy in a patient
treated with eculizumab for haemolytic uraemic syndrome (HUS). This follows the recent description of the complement
factor 3 (C3) activating activity of the enzyme renin and the successful therapeutic use of the direct renin inhibitor aliskiren
in three cases of C3 glomerulopathy/dense deposit disease. We discuss the potential clinical and pathophysiological
implications of these reports on nephropathies linked to complement, from HUS to C3 glomerulopathy to immunoglobulin
A nephropathy as well as the concept of dual complement inhibition for kidney disease.
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In this issue of Clinical Kidney Journal (CKJ), Plasse et al. [1] report
on the use of high-dose aliskiren as an adjunct therapy in a pa-
tient treated with eculizumab for haemolytic uraemic syndrome
(HUS). This follows the recent description of the complement
factor 3 (C3) activating activity of the enzyme renin and the suc-
cessful therapeutic use of aliskiren in three cases of dense de-
posit disease [2]. We discuss the potential clinical and
pathophysiological implications of these reports as well as the
concept of dual complement inhibition for kidney disease.
WHAT IS ALISKIREN?
Aliskiren is a direct renin inhibitor with low bioavailability (2–
3%) and long half-life (40 h) [3]. The European Medicines Agency
lists the indication for the treatment of essential hypertension
in adults, a recommended dose of 150 mg once daily that may
be increased to 300 mg once daily and the contraindication of
the combination with angiotensin-converting enzyme inhibi-
tors (ACEIs) or angiotensin II receptor blockers (ARBs) in
patients with diabetes mellitus or renal impairment [4].
However, aliskiren is not widely used, given that physicians are
more familiar with other less expensive renin–angiotensin sys-
tem (RAS) blockers, and aliskiren cannot be combined with
other RAS blockers for common indications given the subopti-
mal adverse effect profile and lack of clearly demonstrated
advantages of dual RAS blockade with combinations of aliski-
ren, ACEIs and/or ARBs over single RAS blockade [5]. In fact, the
number of PubMed-listed publications on aliskiren has progres-
sively decreased over the past 7 years (Figure 1) [6].
WHAT IS RENIN?
Renin is an aspartyl protease secreted by the juxtaglomerular
apparatus in the kidneys [7]. The main known function of renin
is to cleave angiotensinogen to form angiotensin I, the angio-
tensin II precursor peptide (Figure 2). Renin release is increased
by lower blood pressure inside the afferent arterioles, lower tu-
bular fluid chloride content at the macula densa of the distal tu-
bule and b-adrenergic receptor activity [7, 8]. In addition,
angiotensin II exerts a negative feedback inhibition on renin re-
lease. In this regard, RAS blockade may result in renin release
and chronic dual ARB/ACEI may cause severe juxtaglomerular
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hyperplasia characterized by increased renin staining [9].
Juxtaglomerular cells are specialized smooth muscle cells lo-
cated mainly in the afferent arteriole. Under chronic renin stim-
ulation situations, additional kidney cells may be recruited to
secrete renin. In these circumstances, renin release will ulti-
mately depend on the number of renin-secreting cells [8]. Thus
the highest renin concentrations will be found in glomeruli and
kidneys.
WHAT IS THE NEW INFORMATION ON RENIN?
In 2018, Békássy et al. [2] found that human renin has enzymatic
activity to cleave human C3 into C3a and C3b, that is, renin ini-
tiates the apical event in the alternative pathway for comple-
ment activation (Figure 2). They hypothesized that this may
partly explain the sensitivity of the kidneys to complement-me-
diated injury. They went on to show that aliskiren use in three
girls (ages 7–12 years) with dense deposit disease was associ-
ated with decreased systemic and renal complement activation
(increased circulating C3 and decreased C3a and C5a levels, de-
creased renal C3 and C5b–9 deposition and/or decreased glo-
merular basement membrane thickness) and clinical stability of
the kidney disease over a follow-up period of 4–7 years.
WHAT ARE THE CLINICAL IMPLICATIONS OF
THESE FINDINGS?
If confirmed, these findings may call for preferential use of alis-
kiren to lower blood pressure in C3 glomerulopathy. However,
this is a rare disease. Thus confirmation will take time, and in
the meantime it may seem reasonable to use aliskiren as a first-
line therapy for these patients. Indeed, in an accompanying edi-
torial, Nakano and Nishiyama [10] raised the issue of the safety
of usual RAS blockers for C3 glomerulopathy, because they in-
crease renin activity, and called for clinical studies comparing
aliskiren versus ACEIs or ARBs for this disease. The rationale for
raising questions may extend to other complement activation–
related kidney diseases that represent a growing number of
conditions. An example is immunoglobulin A nephropathy
(IgAN) [11]. And IgAN is also an example of nephropathy for
which classical RAS blockade is currently considered a key ther-
apeutic approach [12]. At the height of interest on aliskiren in
the earlier part of this decade, two clinical studies reported a
decrease in residual albuminuria by aliskiren in IgAN patients
with significant residual albuminuria while on conventional
RAS blockade [13, 14]. More recently, a case report described a
complete proteinuria remission associated with initiation of
aliskiren in an IgAN patient unresponsive to conventional RAS
blockers, steroids and immunosuppressants [15]. However, in
more common diseases, such as IgAN, any change of paradigm
regarding routine clinical care must be preceded by clinical
trials.
HOW DOES THE NEW KNOWLEDGE FIT WITH
OLDER LITERATURE DATA?
Almost 15 years ago, rats harbouring human renin and angio-
tensinogen genes were observed to develop hypertension and
renal complement activation that preceded albuminuria [16].
Aliskiren reduced albuminuria and evidence of complement ac-
tivation, which would be in line with a role for human renin in
activating complement. However, an ARB also prevented com-
plement activation and albuminuria, supporting a direct role of
angiotensin II in these events. Thus, whatever the mechanism,
aliskiren did not appear to offer an advantage over conventional
RAS blockade and this older report would not have clearly pre-
dicted recent findings on the human renin–C3 interaction. Since
recombinant murine renin did not cleave murine C3, the ARB-
related potential increase in regulated murine renin expression
was not expected to modulate C3 activation [2]. The lack of mu-
rine renin impact on murine C3 may have hampered research
into this interaction.
WHAT DOES THE RECENT CKJ REPORT ADD TO
THE EVOLVING CONCEPTS ON RENIN AND
COMPLEMENT?
Plasse et al. [1] report on the use of high-dose aliskiren as an ad-
junct therapy in a haemodialysis patient treated with eculizu-
mab for HUS, thus potentially expanding the range of
complement-related disease where aliskiren may be useful and
adding key information on the impact of dose. Interpretation of
results should depart from the observational and single
nature of the report that does not allow us to exclude that the
natural history of the disease overlapped with aliskiren use.
However, the findings are intriguing, and for rare diseases, sin-
gle case reports may generate hypotheses that improve disease
management. Three key messages were (i) the patient remained
on dialysis despite eculizumab/aliskiren and improvement in
blood pressure and lab parameters, including C3 levels. Thus
success was not complete. (ii) However, an increase in aliskiren
dose to 600 mg/day was followed by an increase in C3 levels and
improvement in other disease parameters within 1 month.
Dosing considerations are discussed below. There are reports of
renal function recovery when eculizumab was initiated after
4 months on dialysis and of recovery of renal function 2.0–
3.5 months after initiation of eculizumab in dialysis-dependent
patients with C3 glomerulopathy or HUS [17]. Thus the observed
time line is a key to link the increase in aliskiren dose, 5 months
after starting eculizumab, to benefit. (iii) Dialysis doctors should
still be familiar with the molecular mechanisms of kidney dis-
ease, as shown by the rapid implementation of advances from
recent reports to patient care.
FIGURE 1: Annual number of PubMed-listed aliskiren publications as of 29
August 2019 [6].
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WHAT IS THE BIOLOGICAL PLAUSIBILITY AND
DOSING IMPLICATIONS OF ALISKIREN
INHIBITION OF RENIN?
In the original report, aliskiren inhibited C3 conversion in vitro
at concentrations 10–>100 mM depending on assay condition
[2]. However, this is well above the mean and upper limit of the
steady-state plasma aliskiren Cmax in healthy volunteers or
chronic kidney disease individuals on a 300-mg daily dose that
may reach up to 0.001–0.002 mM, respectively, for mean and up-
per limit Cmax in the presence or absence of irbesartan [18].
Based on this information, it seems unlikely that aliskiren
inhibits C3 conversion in vivo. In this regard, the doses adminis-
tered to children with dense deposit disease were not reported
[2]. However, aliskiren accumulates in the kidney; in mice, the
kidney:plasma ratio is 20:40 [19]. Another feature is that aliski-
ren has non-linear kinetics. Thus, after single-dose administra-
tion in the dose range of 75–600 mg, a 2-fold increase in dose
results in a 2.3- and 2.6-fold increase in the area under the
curve and Cmax, respectively, and at steady state the non-
linearity may be more pronounced [4]. Thus the eventual local
kidney concentration under steady-state high-dose conditions
is unknown and a sustained dose increase to 600 mg/day, as
done by Plasse et al. [1], may have led to substantially high local
aliskiren levels.
DOES RENIN REPRESENT A LOCAL
COMPLEMENT ACTIVATION SYSTEM?
The local availability of high concentrations of renin together
with local C3 production may result in a local pathway for alter-
native complement activation in the kidney. The local release of
renin may contribute to activate locally released or circulating
C3. In this regard, transplantation experiments involving C3þ/þ
and C3/ mice suggest a key role for locally synthesized C3
(mostly identified in tubular cells) for complement-mediated re-
perfusion damage after kidney ischaemia, whereas circulating
C3 had a negligible effect [20]. In contrast, there is disagreement
on the role of local C3 on albumin overload–induced kidney in-
jury, with the larger study suggesting it does play a role [21, 22].
Since these are murine studies and murine renin does not acti-
vate complement, they do not support a role for renin in murine
complement-mediated disease, but they do raise the issue of
such an interaction in humans in the context of diseases not
usually associated with complement by physicians. In any case,
under physiological conditions, C3 activation by renin may be
controlled by negative regulators of complement activation.
The interaction may eventually have pathological consequen-
ces if complement control systems are disabled. However, the
experimental approach of this hypothesis is not easy and may
involve genetically modified animals expressing human renin.
DUAL COMPLEMENT INHIBITION FOR
COMPLEMENT-MEDIATED KIDNEY DISEASE
The report by Plasse et al. [1] in this issue of CKJ may illustrate a
novel concept for therapy of complement-mediated kidney dis-
ease: dual complement inhibition with eculizumab and high-
dose aliskiren. For the moment, it is a sole case report and we
cannot exclude that they only observed the natural history of
the disease, modified by eculizumab. In any case, the close tem-
poral relationship between the prescription of high-dose aliski-
ren and the improvement in analytical parameters coupled
with the recent report on aliskiren inhibition of C3 processing
and its use in three cases of dense deposit disease may portend
a new era of dual complement inhibition for complement-
related kidney disease [2] (Figure 2).
UNANSWERED QUESTIONS
At present, recent clinical reports of an association between
aliskiren use and improvement in laboratory, pathological and/
or clinical parameters in patients with complement-mediated
diseases raise more questions than answers. What is the rela-
tive contribution of renin and C3bBb to local kidney C3 activa-
tion? Is this different in untreated versus individuals on
FIGURE 2: Molecular pathways for RAS and alternative complement activation with sites of action of aliskiren and eculizumab. Drawn based on novel information on
renin and complement interaction [2]. The dual complement inhibition concept is a hypothetical concept that requires clinical validation and is based on results pub-
lished in this issue of CKJ [1]. Both ACE inhibition and angiotensin receptor blockade increase renin secretion. The C5 inhibitor eculizumab is currently used to treat
complement-related kidney conditions such as atypical HUS (aHUS). Recent publications suggest that renin may also activate C3, and in observational case reports,
aliskiren was associated with benefit in patients with dense deposit disease or aHUS [1, 2]. In the latter case, aliskiren was associated with benefit in association with
eculizumab: the dual complement inhibition concept. ATR1, angiotensin II receptor 1.
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conventional RAS blockade? Does conventional RAS blockade in-
terfere with optimal outcomes in complement-related disease? Or
dual conventional RAS blockade? If RAS blockade results in renin
release, why is there a large body of evidence supporting RAS
blockade as a key nephroprotective manoeuvre even in nephropa-
thies that may be complement mediated? Do renin-secreting
tumours develop complement activation? Do angiotensinogen and
C3 compete for renin? What is the optimal complement activation
inhibitor dose for aliskiren? Will aliskiren move from outdated
dual RAS blockade to novel dual complement inhibition? And,
above all, should aliskiren become the RAS blocker of choice for
complement-mediated kidney disease while we wait for results of
controlled studies? The scientific response to this last question is
unclear. However, it is likely that as word spreads of recent publi-
cations, this becomes the default attitude by physicians.
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